News
-
-
-
PRESS RELEASE
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics announces key patent milestones for Bucillamine in medical countermeasures and infectious diseases, strengthening its strategic position